PlexBio Co., Ltd.

PlexBio Co., Ltd.

TTPEX:6572
6.04
TWD
0.00
(0.00%)
714.14MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.22
0.15
0.34
0.52
1.2
0.89
0.98
1.21
1.84
1.61
1.24
1.23
- -
Basic EPS, GAAP
-3.33
-5.21
-3.94
-4.35
-3.35
-2.32
-1.37
-1.27
-0.51
-0.56
-0.59
-0.6
- -
Free Cash Flow per Basic Share
-4.59
-3.81
-4.11
-4.03
-2.98
-1.04
-1.14
-0.93
-0.71
-0.31
-0.08
-0.77
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
6.19
9.89
5.99
1.69
3.46
7.76
6.42
5.16
4.63
4.09
3.61
3
2.79
Tangible Book Value per Share
6.12
9.61
5.87
1.61
3.44
7.75
6.41
5.15
4.62
4.09
3.61
2.99
2.79
Basic Weighted Avg Shares
37
41
51
51
67
80
103
104
104
104
104
104
104
Sales/Revenue/Turnover
8
6
17
27
81
71
101
125
191
167
128
127
- -
Operating Margin (%)
-1,497.01
-3,374.56
-1,119.95
-769.46
-280.02
-247.82
-146.34
-108.26
-35.01
-38.37
-62.1
-51.65
- -
Depreciation Expense
11
22
18
23
23
27
25
25
20
18
19
16
- -
Net Income, GAAP
-124
-215
-200
-221
-226
-185
-141
-132
-53
-59
-62
-62
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-1,541.33
-3,513.64
-1,168.48
-832.15
-278.8
-259.89
-139.19
-105.32
-27.79
-35.01
-48.13
-49.15
- -
Working Capital
218
386
182
-5
174
807
678
540
502
424
367
300
283
LT Debt
- -
- -
- -
- -
- -
2
3
1
2
2
2
1
- -
Total Equity
315
503
305
86
241
797
662
534
479
424
374
310
289
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-52.6
-49.58
-113.03
-138.17
-35.64
-19.33
-21.99
-10.48
-12.95
-15.43
-18.24
- -

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
9
8
5
LT Borrowings
- -
- -
- -
LT Finance Leases
5
1
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
104
104
104
Market Capitalization
1,057
806
714

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
488
417
374
Cash, Cash Equivalents & STI
339
328
283
Accounts Receivable, Net
28
1
26
Inventories
51
50
46
Total Current Liabilities
169
117
90
Payables & Accruals
- -
- -
- -
ST Debt
9
8
5
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.26%
-13.99%
-17.09%
Free Cash Flow
66.07%
129.82%
820.02%
Net Income, GAAP
-8.57%
-9.91%
1.36%
Sales/Revenue/Turnover
50.98%
7.92%
-0.76%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
128
2025
- -
- -
127
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.59
2025
- -
- -
-0.6
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

CEO
Ting Tsao
Full Time Employees
20
Sector
Health technology
Industry
Medical specialties
Address
No. 351, Yangguang Street Taipei TPE Taiwan 11491
IPO Date
Feb 26, 2016
Business
PlexBio Co., Ltd. innovates and produces advanced in vitro diagnostic solutions for applications in molecular biology and immunology. The company furnishes comprehensive workflow guidance; automated extraction systems for sample preparation; the IntelliPlex platform, engineered around its proprietary πCode™ technology for high-throughput, sample-to-result multiplexing assays; specialized oncology panels for detecting lung cancer, various mutations, and gene rearrangements; IntelliPlex test kits for SARS-CoV-2 and influenza, alongside variant analysis kits for SARS-CoV-2; and essential πCode™ coupling reagents. Recently, PlexBio has broadened its strategic alliances, including a significant partnership with Japan's Denka Group to co-develop automated infectious disease diagnostic platforms and expand its Contract Development and Manufacturing Organization (CDMO) services. The company also obtained FDA Certification for its IntelliPrep TRIO System, enabling market expansion into Korea. Established in 2009, PlexBio Co., Ltd. maintains its headquarters in Taipei, Taiwan.